A phase II study investigating safety and efficacy of dose reduced fludarabine, cyclophosphamide and obinutuzumab versus chlorambucil and obinutuzumab in untreated, comorbid, elderly patients with chronic lymphocytic leukemia (CLL)

被引：0
|
作者：
Mulligan, Stephen [1 ,2 ]
Tam, Constantine [1 ,2 ]
Badoux, Xavier [1 ,2 ]
Kuss, Bryone [1 ,2 ]
机构：
[1] Australasian Leukaemia & Lymphoma Grp, Richmond, VI, Australia
[2] CLL Australian Res Consortium, Richmond, VI, Australia
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
32
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients
    Kutsch, Nadine
    Holmes, Emily Eva
    Robrecht, Sandra
    Schueler, Gudrun
    Vehling-Kaiser, Ursula
    Decker, Thomas
    Mueller-Hagen, Sigrun
    Heinisch, Karin
    Boettcher, Sebastian
    Ritgen, Matthias
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Fink, Anna Maria
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    Wendtner, Clemens-Martin
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 478 - 482
  • [22] COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGUESE PATIENTS THAT ARE UNSUITABLE FOR FULL-DOSE FLUDARABINE BASED THERAPY
    Paquete, A.
    Miguel, L. S.
    Pereira, C.
    Pinto, C. G.
    VALUE IN HEALTH, 2015, 18 (07) : A463 - A464
  • [23] Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
    Visentin, Andrea
    Mauro, Francesca Romana
    Catania, Gioachino
    Fresa, Alberto
    Vitale, Candida
    Sanna, Alessandro
    Mattiello, Veronica
    Cibien, Francesca
    Sportoletti, Paolo
    Gentile, Massimo
    Rigolin, Gian Matteo
    Quaglia, Francesca Maria
    Murru, Roberta
    Gozzetti, Alessandro
    Molica, Stefano
    Marchetti, Monia
    Pravato, Stefano
    Angotzi, Francesco
    Cellini, Alessandro
    Scarfo, Lydia
    Reda, Gianluigi
    Coscia, Marta
    Laurenti, Luca
    Ghia, Paolo
    Foa, Robin
    Cuneo, Antonio
    Trentin, Livio
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Brown, Jennifer R.
    Eichhorst, Barbara
    Ghia, Paolo
    Kater, A. P.
    Li, Jianyong
    Khurana, Sudha
    Elhamy, Mostafa
    Wang, Min Hui
    Seymour, John F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S221 - S222
  • [25] A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Castro, Januario E.
    Choi, Michael Y.
    Amaya-Chanaga, Carlos I.
    Nguyen, Natalie
    MacCarthy, Colin
    Kipps, Thomas J.
    BLOOD, 2016, 128 (22)
  • [26] Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
    Woyach, Jennifer
    Ruppert, Amy S.
    Perez, Gabriela
    Booth, Allison M.
    Feldman, Diane
    Dib, Elie G.
    Jatoi, Aminah
    Le-Rademacher, Jennifer
    Heerema, Nyla A.
    Lozanski, Gerard
    Little, Richard
    Ding, Wei
    Hill, Brian T.
    Stone, Richard M.
    Mandrekar, Sumithra J.
    Byrd, John C.
    BLOOD, 2019, 134
  • [27] Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
    Othman Al-Sawaf
    Can Zhang
    Hyun Yong Jin
    Sandra Robrecht
    Yoonha Choi
    Sandhya Balasubramanian
    Alex Kotak
    Yi Meng Chang
    Anna Maria Fink
    Eugen Tausch
    Christof Schneider
    Matthias Ritgen
    Karl-Anton Kreuzer
    Brenda Chyla
    Joseph N. Paulson
    Christian P. Pallasch
    Lukas P. Frenzel
    Martin Peifer
    Barbara Eichhorst
    Stephan Stilgenbauer
    Yanwen Jiang
    Michael Hallek
    Kirsten Fischer
    Nature Communications, 14
  • [28] Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Zhang, Can
    Jin, Hyun Yong
    Robrecht, Sandra
    Choi, Yoonha
    Balasubramanian, Sandhya
    Kotak, Alex
    Chang, Yi Meng
    Fink, Anna Maria
    Tausch, Eugen
    Schneider, Christof
    Ritgen, Matthias
    Kreuzer, Karl-Anton
    Chyla, Brenda
    Paulson, Joe
    Pallasch, Christian P.
    Frenzel, Lukas P.
    Peifer, Martin
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Jiang, Yanwen
    Hallek, Michael
    Fischer, Kirsten
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [29] Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience
    Tadmor, Tamar
    Herishanu, Yair
    Braester, Andrei
    Bairey, Osnat
    Aviv, Ariel
    Rahimi-Levene, Naomi
    Fineman, Riva
    Levi, Itai
    Yuklea, Mona
    Ruchlemer, Rosa
    Shvideland, Lev
    Polliack, Aaron
    BLOOD, 2018, 132
  • [30] Low dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and refractory chronic lymphocytic leukemia
    Forconi, Francesco
    Toraldo, F.
    Sozzi, E.
    Lenoci, M.
    Fabbri, A.
    Gozzetti, A.
    Tassi, M.
    Raspadori, D.
    Lauria, Francesco
    BLOOD, 2007, 110 (11) : 612A - 612A
12345